EXEL

Exelixis, Inc. 10-Q Summary: Quarter Ended March 31, 2005

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2005 for Exelixis, Inc., a biotechnology company focused on drug discovery for cancer, metabolic disorders, and cardiovascular disease. The company operates primarily through internal research and development and strategic collaborations with major pharmaceutical partners, including GlaxoSmithKline (GSK) and Bristol-Myers Squibb.

Key Financial Metrics

Note: Total Debt includes $115,000 in convertible promissory notes, $18,633 in long-term notes/bank obligations, and $8,016 in current portions of notes.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased by approximately 8% ($1.0 million) compared to Q1 2004. This was driven by increased research funding from GSK ($1.9 million increase) and Sankyo Co., Ltd. ($1.0 million increase), partially offset by the cessation of upfront payment amortization from Bristol-Myers Squibb.
• Expense Management: Research and Development (R&D) expenses decreased by 3% to $33.3 million, primarily due to a 29% reduction in lab supplies following the termination of combinatorial chemistry collaborations. However, consulting expenses rose 25% due to clinical trial activities.
• Liquidity Position: Cash and cash equivalents decreased by $16.7 million during the quarter. Total liquidity (including short-term investments and restricted cash) stood at approximately $139.1 million.
• Collaboration Amendments: In January 2005, the GSK collaboration was amended to focus on 12 specific internal programs. GSK purchased an additional 1.0 million shares of Exelixis stock for $11.1 million, with a $2.2 million premium to be recognized as revenue over time.

Guidance, Outlook, and Risks

• Outlook: Management anticipates maintaining operations for at least the next 12 months using current cash, investments, and expected collaborator funding. The company expects to incur substantial losses for the foreseeable future as it advances its pipeline.
• Pipeline Progress: The company expects eight compounds in active clinical trials in 2005. Key milestones include the ongoing Phase 3 trial for XL119 (bile duct tumors) and the initiation of Phase 1 trials for XL880, XL820, XL844, and XL184.
• Subsequent Events: In May 2005, Exelixis filed the third of three required INDs to trigger a $30.0 million milestone payment from GSK. Additionally, a $5.0 million milestone was triggered by submitting two new development candidates to GSK.
• Key Risks:
  • Financing Needs: The company must raise additional capital to fund operations and clinical trials. Failure to do so could force a curtailment of operations.
  • Debt Covenants: Exelixis must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million to comply with GSK loan covenants. As of March 31, 2005, the company was in compliance ($74.0M working capital; $139.1M cash/investments).
  • Convertible Note: A $30 million convertible promissory note to PDL matures in May 2006. If not converted, it must be repaid in cash.
  • Regulatory Uncertainty: Clinical trials are lengthy and uncertain; failure to demonstrate safety or efficacy could delay or prevent regulatory approval.

Investor Verification Checklist

• Verify the status of the $30 million GSK milestone triggered by the May 2005 IND filings and the timing of cash receipt.
• Confirm the company's ability to meet the May 2006 maturity of the $30 million PDL convertible note or its conversion terms.
• Monitor the Phase 3 clinical trial results for XL119 (becatecarin) for bile duct tumors, as this is the most advanced asset.
• Review the Genoptera collaboration termination and the recognition of the $10.9 million early termination fee paid in April 2005.
• Assess the impact of the upcoming adoption of SFAS 123R (Share-Based Payment) in Q1 2006 on future net loss and earnings per share.